Donald Trump’s warning of a 100% tariff on branded and patented pharmaceutical products has set the industry buzzing. While Indian pharma exports to the US totalled $10.5 billion in 2024–25, only $1 billion came from branded formulations, with $9.5 billion driven by generics. Analysts believe that imposing tariffs on generics would be politically difficult in the US, given the potential rise in drug prices for patients. But branded and patented products may feel the pressure, with companies like Sun Pharma possibly seeing an impact. In this video, we break down the numbers, the possible winners and losers, and what this means for the future of Indian pharma in the American market.

See Full Page